How Can Manufacturers Improve Efficiency in API Intermediate Development?

2026-08-27

1. Where Should You Focus First: Route Design or Reaction Optimization?

The most significant efficiency gain comes before any chemical is synthesized. It comes from rethinking the synthetic route itself. In our experience, many developers default to the literature route for their Intermediates, even when that route was designed for discovery chemistry, not manufacturing. A route that works well on a gram scale may involve expensive reagents, low yielding steps, or hazardous intermediates. In our factory, we challenge the route at the very beginning. We ask: can we replace a column chromatography step with a simple crystallization? Can we switch from a high boiling solvent to one that is easily recovered? Can we combine two steps into a one pot reaction? For one of our clients, we redesigned the synthesis of a key Intermediate from 8 steps to 5 steps, eliminating two costly purification steps. The overall yield increased from 22 percent to 47 percent, and the production time was cut by 60 percent.

The table below shows the impact of different optimization strategies on Intermediate development efficiency based on our internal records.

Optimization strategy	Average yield improvement	Typical time saved	Implementation difficulty
Route redesign (fewer steps)	+18 – 35%	4 – 8 weeks	High (requires expertise)
Solvent substitution (greener, recoverable)	+5 – 12%	2 – 3 weeks	Medium
Catalyst screening for higher selectivity	+10 – 25%	3 – 6 weeks	Medium
Reaction parameter DOE (temperature, time)	+6 – 15%	2 – 4 weeks	Low to medium
Work up simplification (crystallization vs chromatography)	+8 – 20%	1 – 3 weeks	Low

The message is clear: invest the time upfront to map out the optimal route for your Intermediates. The cost of a few weeks of extra development is far less than the cost of running an inefficient process for years.

2. How Can You Avoid the Scale Up Trap That Kills Efficiency?

One of the most painful moments in Intermediate development is when a reaction that worked perfectly at the 100 gram scale fails dramatically at the 100 kilogram scale. Heat transfer is different. Mixing is different. The exotherm that was manageable in the lab becomes a safety hazard in the plant. In our factory, we address scale up risk by using a three stage approach. The first stage is a mini plant trial using a 20 liter reactor that mimics the geometry of the production scale vessel. The second stage is a pilot run at 500 liters to confirm the heat and mass transfer models. The third stage is the full production run, with a predefined set of critical process parameters. We have developed a scale up predictor tool that uses computational fluid dynamics to estimate the mixing time and heat removal capacity for any given vessel. This tool has helped us avoid scale up failures in over 90 percent of the projects we have handled. For one client, we scaled an Intermediate from 50 grams to 500 kilograms with no loss of yield or purity, simply because we had modeled the agitation and temperature control accurately. The investment in scale up engineering pays back many times over.

3. What Role Does Analytical Technology Play in Compression of Development Time?

Waiting for HPLC results to decide the next step is a major time sink. In our factory, we have implemented Process Analytical Technology (PAT) that allows us to monitor reactions in real time. Using inline FTIR and Raman spectroscopy, we track the disappearance of starting materials and the formation of the Intermediate without taking samples. This reduces the analysis time from 30 minutes per sample to seconds, and it eliminates the sampling error. For a complex multi step Intermediate, we have reduced the total development time from 18 months to 11 months by using PAT. The data also helps us identify the exact endpoint of the reaction, avoiding overcooking that creates impurities. We also use automated sampling systems for off line HPLC, which run 24/7 and allow our chemists to make decisions based on overnight data rather than waiting for the next morning. At Sandoo Pharmaceuticals and Chemicals Co.,Ltd., we treat analytical development as a parallel track to synthesis development, not as a downstream activity.

4. How Can You Compress Impurity Profiling Without Compromising Quality?

Impurity profiling is often the longest part of Intermediate development because it requires isolating and identifying every impurity above the reporting threshold. In our factory, we have adopted a targeted approach. We first use a mass selective detector to identify all impurities. Then we prioritize the impurities that are most likely to carry over or degrade the final API. We do not spend equal time on every peak; we focus our resources on the ones that matter. This targeted impurity strategy has cut the profiling time by 40 percent without increasing the risk to the final product. For a recent project, we developed an Intermediate for a cardiovascular API. We identified 12 impurities initially, but after a carryover study, we determined that only 3 of them had any potential to persist through the final API synthesis. We focused our validation on those 3 impurities and completed the entire impurity package in 6 weeks instead of the usual 14. This approach is not a shortcut; it is a data driven prioritization that is accepted by regulators when the carryover data is sound.

Frequently Asked Questions About API Intermediate Development Efficiency

Question 1: What is the single biggest time waster in early stage Intermediate development, and how can it be avoided?

Answer: The biggest time waster is repeating failed reactions without understanding why they failed. Many chemists change one parameter at a time, but because the failure could be due to multiple interacting factors, this trial and error approach is extremely slow. In our factory, we use Design of Experiments (DoE) from the very beginning. Instead of changing temperature, then time, then concentration separately, we run a designed matrix that tests all variables simultaneously. This tells us which factors are significant and whether they interact. For one Intermediate, our DoE approach identified that the combination of temperature and pH had a synergistic effect that was not visible when they were tested independently. We went from 6 weeks of guesswork to 2 weeks of systematic data collection. The cost of training chemists in DoE is minimal compared to the time saved. We also recommend documenting every failed experiment in a searchable database, so that future developers can learn from the past.

Question 2: How do you balance the need for speed against the regulatory requirement for comprehensive characterization of Intermediates?

Answer: The key is to separate the data that is truly required for regulatory submission from the data that is useful but not mandatory. For Intermediates, the regulatory expectation is that you have a robust control strategy. This means you need to know the impurity profile, the process limits, and the stability data. However, you do not need to isolate and fully characterize every single impurity if you can show that it is not a risk to the final API. In our practice, we use a stepwise approach: we first generate enough data to demonstrate that the process is consistent, and then we continue to collect data during the validation batches. We also use analytical method validation as an opportunity to generate additional data. For example, a forced degradation study can be designed to simulate the impact of realistic process variations, thereby generating stability data and impurity data at the same time. This approach has helped our clients reduce their regulatory submission timelines by 3 to 4 months.

Question 3: What are the most effective ways to transfer Intermediate technology from R&D to manufacturing without losing efficiency?

Answer: The transfer is often where the most efficiency is lost, because the R&D team and the manufacturing team have different incentives and different knowledge bases. In our factory, we use a three step transition process. Step one: joint development where the R&D chemist works side by side with the manufacturing engineer to produce the first pilot batch. Step two: the manufacturing engineer leads the next pilot batch while the R&D chemist observes. Step three: the manufacturing engineer runs the batch independently, with the R&D chemist available for consultation. This three step process ensures that all the tacit knowledge—like the color change that indicates the reaction is complete or the sound of the agitator that indicates the correct viscosity—is transferred. We also create a detailed batch sheet that includes photographs of key stages. For a recent transfer of an Intermediate for an antiviral drug, this process reduced the ramp up time from 6 months to 10 weeks. At Sandoo Pharmaceuticals and Chemicals Co.,Ltd., we treat technology transfer as a collaborative partnership, not a handover.

Final Summary

Improving efficiency in API Intermediate development is not about one single breakthrough. It is about making deliberate improvements at every stage: route design, reaction optimization, scale up modeling, and impurity prioritization. Each improvement is small, but together they transform the development timeline. Our factory has applied these principles to hundreds of Intermediates, helping our clients bring their products to market faster and at a lower cost. Sandoo Pharmaceuticals and Chemicals Co.,Ltd. is committed to being a partner in that journey.

Previous:No News

Next:No News